Actinium Pharmaceuticals logo
Actinium Pharmaceuticals
ATNM | AMEX
Chart Builder DCF Calculator
$1.49
-$0.15 (-9.15%)
At close: Nov 16, 2026, 4:00 PM ET
$1.42
-$0.07 (-4.37%)
After-hours: Nov 16, 2026, 6:06 PM ET

Actinium Pharmaceuticals Company Profile

Company profile explained

Company Profile

Actinium Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm dedicated to developing and commercializing treatments, primarily focusing on those for bone marrow transplant (BMT) or other cellular and adoptive cell therapies. Its leading drug candidate, I-131 apamistamab (known as Iomab-B), is currently in a crucial Phase III clinical trial for its role in conditioning elderly patients with relapsed or refractory acute myeloid leukemia prior to BMT. Additionally, Iomab-B is being evaluated in a Phase I study for its use with CD19-targeted CAR T-cell therapy, a partnership with Memorial Sloan Kettering Cancer Center. The company's pipeline also includes several clinical and preclinical development programs that harness various isotopes such as Actinium-225, Iodine-131, and Lutetium-177. These programs are designed to target a range of validated cancer markers, including CD45, CD33, CD38, CD47, HER2, and HER3. Their applications span targeted conditioning regimens for cell and gene therapies, such as bone marrow transplantation, and as standalone or combination cancer therapeutics. Actinium has established strategic alliances, including a collaboration with Astellas Pharma, Inc. to create theranostics for solid tumor indications. Another partnership is with EpicentRx, Inc., concentrating on an innovative CD47 immunotherapy delivered via targeted radiotherapy. Furthermore, the company is working with AVEO Oncology on developing a HER3-targeting Antibody-Radio Conjugate (ARC) for solid tumors. Incorporated in 2000, Actinium Pharmaceuticals, Inc. is headquartered in New York, New York.

Key Executives

Name Position
Sandesh C. Seth CEO, Principal Financial Officer & Chairman
Adeela Kamal Chief Scientific Officer
Lynn Bodarky Chief Business Officer
Madhuri Vusirikala Vice President of Clinical Development BMT & Cellular Therapy
Paul Diamond Vice President of Patent & Legal Counsel
Steffen Heeger Chief Medical Officer

Latest SEC Filings

Date Type Title
Oct 16, 2026 4 Filing
Oct 16, 2026 3 Filing
Oct 15, 2026 ARS Filing
Oct 15, 2026 DEF 14A Filing
Oct 15, 2026 8-K Current Report
Oct 09, 2026 S-8 Filing
Sep 10, 2026 3 Filing
Sep 10, 2026 3 Filing
Sep 04, 2026 4 Filing
Sep 04, 2026 4 Filing
View All SEC Filings ➞
Actinium Pharmaceuticals
Actinium Pharmaceuticals logo
Country United States
IPO Date Dec 27, 2012
Industry Biotechnology
Sector Healthcare
Employees 27
CEO Sandesh C. Seth

Contact Details

100 Park Avenue New York City, New York 10017 United States

Stock Details

Ticker Symbol ATNM
Exchange AMEX
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001388320
CUSIP Number 00507W206
ISIN Number US00507W2061
SIC Code 2834

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.